Kewaunee's EPS Was Cut in Half. The Backlog Says It's Timing, Not Lost Demand

Kewaunee Scientific builds the lab furniture, fume hoods, and clean-air equipment that sit inside pharma and hospital projects, and it just reported a quarter that reads like a shrink story. First-quarter fiscal 2027 sales fell 6.7% to $66.3 million, and diluted EPS nearly halved, dropping to $0.58 from $1.04 a year earlier. On its face that is a business losing momentum. The question is whether the market has already decided that is permanent — because at a ~$100 million market cap, it appears to have.

The headline number flatters the doom. Peel the quarter apart and most of the earnings decline is near-term noise, not lost demand. Domestic lab products sales fell 6.4%, and the company explains the drop as lower manufacturing volumes in a soft life-sciences market, offset partly by a stronger education market. The international segment, where Kewaunee runs turnkey laboratory projects in India, sold 7.8% less yet grew net earnings 23.5% on a richer mix of projects. And a chunk of the corporate loss widening came from a discrete, non-recurring item: the company settled long-term incentive awards in cash specifically to reduce future dilution.

The line that should calm a skeptic most is management's own framing. CEO Thomas Hull said quoting activity remains strong and that "project award and release timelines remain extended due to broader geopolitical and economic uncertainty". That is the language of a lumpy, project-driven business whose revenue timing it controls poorly — not of a company losing orders. And the backlog backs him up: it ticked up to $169.0 million from $165.9 million three months earlier.

Here is the honest catch, and it is the whole tension of the story. Kewaunee's revenue story has consistently outrun its profit story. It just finished a record fiscal 2026 — revenue up 17.3% to $282 million — yet diluted EPS actually fell to $3.22 from $3.83. The engine of that growth was the November 2024 acquisition of Nu Aire, a maker of biological safety cabinets. Nu Aire added roughly 20% to the domestic lab products segment's sales, but segment EBITDA was flat year over year. In plain terms, Kewaunee bought scale that did not immediately buy earnings, at the top of a life-sciences capex cycle that has since cooled. Two straight quarters of lower EPS on top of record revenue is the market's evidence that this is structural, not timing.

So the whole debate comes down to a single question the numbers cannot yet answer: can the stabilized backlog convert into shipments at healthier margins, or does the acquired business permanently dilute what Kewaunee earns per dollar of sales? Nothing in this quarter settles it. The price, though, already assumes the bear case.

Consider what the market is charging for the answer. The stock carries a market cap near $100 million against a book value of about $77 million — roughly 1.3x book. Enterprise value sits around $137 million against roughly $22 million of trailing EBITDA, a multiple near 6x. That is not a price that assumes the profit slump reverses; that is a price that assumes it is permanent. Meanwhile the balance sheet has been getting cleaner rather than tighter: cash was about $10.3 million at quarter end, and long-term debt net of a sale-leaseback fell to roughly $13.8 million, taking net debt-to-equity down to 0.25-to-1. A company this small that has paid down the acquisition debt and stabilized backlog is not in distress.

The only problem is that cheap on its own is not a thesis — a falling knife lands at a lower multiple eventually. The edge here is conditional, and the condition is observable. At roughly 6x trailing EBITDA for a business that generated $22.4 million of EBITDA in its record year, the stock does not price in the earnings power the current backlog already implies. But it only pays off if the life-sciences cycle and project timing normalize and the domestic segment's margins recover with volume. That is the break condition; until the conversion shows up in reported margins, the divergence between a ~6x multiple and a record-profit year remains an argument in need of proof, not a done deal.